Intra-Cellular Therapies to Present Results From Phase I/II

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intra-Cellular Therapies to Present Results From Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia at the American Neurological Association 139th Annual Meeting

NEW YORK, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will present a poster on ITI-007, the Company's lead drug candidate for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders, at the American Neurological Association 139th Annual Meeting. The meeting will be held October 12-14, 2014, in Baltimore. The poster presentation will feature results from ITI-007-200, the Company's Phase I/II clinical trial in healthy geriatric subjects and patients with dementia, including Alzheimer's disease.

ITI-007-200 Poster Presentation :

Poster #M1302: "ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders". To be presented on Monday, October 13th from 11:00 A.M. to 7:00 P.M EDT. Location: Marriott Waterfront Hotel, Harborside Ballroom.

About Intra-Cellular Therapies

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS"). The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of cognitive deficits in schizophrenia and other CNS disorders. The Company is also developing inhibitors against additional targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as cardiovascular disease.

Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 212-923-3344 Burns McClellan, Inc. Lisa Burns/Angeli Kolhatkar (Investors) Justin Jackson (Media) 212-213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 49

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 139

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 93

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 110

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 69

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Products Secures $140 Million in NASA Liquid Hydrogen Contracts

Updated Category News Views 85

Air Products Receives Significant NASA Contracts Air Products, a leading supplier in the industrial gases market, recently announced an impressive contract award from NASA valued at over $140 million. This contract aims at supplying liquid hydrogen for various NASA facilities, most notably the renowned Kennedy Space Center and other significant sites where vital space...

Continue Reading
Navigating Market Realities: A Look Ahead for Investors

Updated Category News Views 158

The Uncomfortable Truth About Market Valuations Many investors may feel uneasy hearing this, but it’s essential to face the real data regarding market potential. After analyzing the last 40 years of market information from various developed economies, including movements in China, the reality might deter those banking on robust returns in the forthcoming decade. There's...

Continue Reading
Sodexo Unveils Its Universal Registration Document for 2025

Updated Category News Views 367

Introduction to Sodexo's Fiscal 2025 Document Sodexo has made significant strides in enhancing transparency and providing essential information through its recently filed Fiscal 2025 Universal Registration Document (URD). This document, which is now accessible to investors and stakeholders, showcases the company's ongoing commitment to accountability and sustainability....

Continue Reading
Paratus Energy's Q4 2025 Results: Key Indicators to Analyze

Updated Category News Views 197

Paratus Energy Services Ltd. (PLSV) is about to drop its unaudited interim Q4 2025 financial results on February 27, 2026. But here’s the kicker—traders are left with scant intel leading into this call, and that can rattle markets. First off, let’s talk about the earnings whispers. The usual playbook includes scouring through EPS projections and revenue figures, but...

Continue Reading
Keefe Adjusts Rating for Bank of N.T. Butterfield Amid Challenges

Updated Category News Views 72

Keefe Downgrades the Bank of N.T. Butterfield Stock Rating Recently, Keefe, Bruyette & Woods revised its recommendation for Bank of N.T. Butterfield (NYSE: NTB) stock, shifting the rating from Outperform to Market Perform. The price target has also been adjusted from $44 to $41. This reflects the bank's forecast of significant net interest income (NII) challenges...

Continue Reading